Logo

Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

Share this

Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

Shots:

  • Novartis gets an exclusive WW right to develop and commercialize therapeutic applications for FAP assets including FAPI-46 and FAPI-74 under its collaboration with iTheranostics- which is an affiliate of SOFIE Biosciences
  • The agreement also consists of co-exclusive rights for Novartis to develop imaging applications for FAP assets
  • The company will continue to reimagine cancer care through the development of a robust radioligand therapy portfolio and actively investigate across multiple tumor types

  Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions